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Background: Acute worsening of renal function, an independent risk factor for adverse outcomes in acute
decompensated heart failure (ADHF), occurs as a consequence of new onset kidney injury (AKI) or acute
deterioration of pre-existed chronic kidney disease (CKD) (acute-on-chronic kidney injury, ACKI). However, the
possible difference in prognostic implication between AKI and ACKI has not been well established.
Methods: We studied all consecutive patients hospitalized with ADHF from 2003 through 2010 in Nanfang
Hospital. We classified patients as with or without pre-existed CKD based on the mean estimated glomerular
filtration rate (eGFR) over a six-month period before hospitalization. AKI and ACKI were defined by RIFLE criteria
according to the increase of the index serum creatinine.
Results: A total of 1,005 patients were enrolled. The incidence of ACKI was higher than that of AKI. The proportion
of patients with diuretic resistance was higher among patients with pre-existed CKD than among those without
CKD (16.9% vs. 9.9%, P = 0.002). Compared with AKI, ACKI was associated with higher risk for in-hospital mortality,
long hospital stay, and failure in renal function recovery. Pre-existed CKD and development of acute worsening of
renal function during hospitalization were the independent risk factors for in-hospital death after adjustment by the
other risk factors. The RIFLE classification predicted all-cause and cardiac mortality in both AKI and ACKI.
Conclusions: Patients with ACKI were at greatest risk of adverse short-term outcomes in ADHF. Monitoring eGFR
and identifying CKD should not be ignored in patients with cardiovascular disease.
Keywords: Acute decompensated heart failure, Acute kidney injury, Acute-on-chronic kidney injury, OutcomeBackground
Acute decompensated heart failure (ADHF) is one of the
leading causes of hospitalization worldwide. More than
70% of patients hospitalized for ADHF will experience
acute worsening of renal function, which is associated
with significantly poor outcomes [1-7]. Patients with
ADHF are commonly accompanied by the co-
morbidities such as hypertension, diabetes mellitus, and
atherosclerosis which are the risk factors for chronic* Correspondence: ffhouguangzhou@163.com
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reproduction in any medium, provided the orkidney disease (CKD). The Acute Decompensated Heart
Failure National Registry, a large database of patients
with ADHF requiring hospitalization in the United
States, reported that 30% had an additional diagnosis
consistent with CKD [8]. Therefore, acute worsening of
renal function in ADHF might be a consequence of new
onset kidney injury (AKI) or acute deterioration of pre-
existed CKD (acute-on-chronic kidney injury, ACKI).
Increasing evidence has shown that CKD contributes to
impairment of cardiovascular structures and function [9].
Thus, patients with AKI and ACKI may have different im-
pact on outcomes and unique responses to therapeutic
regimens. However, few studies have done to compare the
clinical characteristics between AKI and ACKI, particu-
larly the impact on outcomes. It remains unclear whethertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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verse outcomes or whether it merely serves as a marker of
advanced cardiac/or renal dysfunction.
The present study was performed to compare the im-
pact on outcomes of AKI and ACKI in a cohort of 1,005
Chinese patients with ADHF. We aimed to test the hy-
potheses that patients with ACKI, as opposed to those
with AKI, may be at greater risk of adverse outcomes
during hospitalization in the setting of ADHF.
Methods
The study was approved by the Review Board of Nan-
fang hospital. A total of 1,230 patients with ADHF were
hospitalized to the Coronary Care Unit (CCU) in Nan-
fang hospital, Guangzhou, between Jan 1, 2003, and Dec
31, 2010. Data on estimated glomerular filtration rate
(eGFR) before admission were available for 1,005 of
these patients (81%).
Identification of patients
The integrated medical record system of the hospital,
identified each patient with a unique number, served as
the basis for our retrospective analysis. The diagnosis of
ADHF was based on European Society of Cardiology
Criteria [10]. The patients discharged with the diagnosis
codes of heart failure according to the International
Classification of Disease, Ninth Revision, Clinical Modi-
fication [11], were considered for inclusion in the study.
If a patient was hospitalized more than once for ADHF
during the study period, only the data from the first ad-
mission were analyzed.
The exclusion criteria included severe aortic stenosis,
pulmonary thromboembolism, cardiac tamponade, car-
diogenic shock, heart failure following cardiac surgery,
or multi-organ failure. Patients were also excluded if
they had chronic and severe renal failure (chronic dialy-
sis or eGFR below 30 ml/min/1.73 m2 before admission)
or worsening of renal function occurred following sur-
gery or administration of potentially nephrotoxic agents
such as contrast medium. Subjects who had no records
of serum creatinine values over 6-month period before
admission or during hospital were not included in
the study.
Data extraction
Data were collected on the patient’s demographic char-
acteristics and clinical manifestations on admission. Data
on coexisting cardiovascular conditions in each patient
were also extracted with the use of all relevant ICD
codes. Data on laboratory analysis were extracted from
the Laboratory Information System of Nanfang hospital.
To verify the accuracy of chart abstraction, an inde-
pendent abstractor re-evaluated information in four cat-
egories (creatinine, inclusion and exclusion criteria, anddischarge dates). Serum creatinine values for all 1,005
patients in the final study population were checked, and
no discrepancies were detected. In addition, comprehen-
sive examinations of all data fields were completed in a
subset of 10% of the subjects. Less than 0.5% discrep-
ancy was detected.
Definition of covariates and category
We identified all patients with mean eGFR (at least 3
measurements) more than 30 ml/min/1.73 m2 over a 6-
month period before admission. This eGFR value was
termed the “index eGFR”. We estimated the GFR using
the simplified Modification of Diet in Renal Disease
(MDRD) equation [12], which is accepted as a valid
method for estimating glomerular filtration in patients
with heart failure [13]. We also estimated the GFR with
the Chronic Kidney Epidemiology Collaboration equa-
tion (CKD-EPI) which has been shown to be more ac-
curate in various populations including Asian [14,15].
The results obtained from the two equations were com-
parable. Thus, eGFR values in the present study were
expressed as that calculated with CKD-EPI equation.
Since creatinine is not in steady state when AKI occurs,
it is not appropriate to calculate the GFR from serum
creatinine [16]. We used the peak increase in serum cre-
atinine to assign a category in the RIFLE classification.
We did not use urine output as a criterion for classifica-
tion, because it was not possible to obtain accurate
records of urine output.
AKI group
Patients with index eGFR were classified as having AKI
when their serum creatinine was increased by 50%,
100%, or 200% during hospitalization. 93% of patients in
the cohort reached their peak serum creatinine within
the first 7 days of hospitalization. We used maximum
serum creatinine level to category RIFLE class.
ACKI group
The Acute Dialysis Quality Initiative (ADQI) group recom-
mends separate criteria for the diagnosis of ACKI. They
assigned these patients to the Fc category (where F is fail-
ure and c is chronic kidney disease) when their serum cre-
atinine had increased to 350 μmol/L. The ADQI group did
not assign a category to those in whom serum creatinine
did not rise as high as 350 μmol/L. Patients in our study
were defined as CKD when their index eGFR values were
arrange from 60 ml/min/1.73 m2 to 30 ml/min/1.73 m2.
We excluded patients with eGFR below 30 ml/min/
1.73 m2, since it may be difficult to distinguish between the
final stages of progression to end stage renal disease and
potentially reversible acute worsening of renal function
due to relatively small changes in GFR leading to large
changes in serum creatinine [17].
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study according to previous report [17]:
1. Risk: serum creatinine increased by 50% or more
from index serum creatinine but had not reached
350 μmol/L.
2. Injury: serum creatinine increased by 100% or more
from index serum creatinine but had not reached
350 μmol/L.
3. Failure: serum creatinine increased by 200% or more
from index serum creatinine or serum creatinine
had increased to 350 μmol/L as the ADQI group
recommends.
Patients were excluded when any rise in serum cre-
atinine was not sustained for 24 hours.
Definition of renal recovery
Renal recovery was defined as previously reported [17].
1. Full recovery: Serum creatinine concentrations fell
below or to the index .
2. Partial recovery: Serum creatinine remained above
the index.
3. Failure to recover: Dialysis dependent at 90 day.
Diuretic resistance
Diuretic resistance was defined as persistent pulmonary
congestion with or without acute worsening of renal
function despite attempts at diuresis (repeated doses of
80 mg furosemide, or greater than 240 mg furosemide
daily, or combination diuretic therapy including loop
diuretics with thiazide or aldosterone antagonist). The
doses of diuretics were calculated according to the pre-
scription records in chart review.
Statistical analysis
The continuous variables were presented as the mean±
standard deviation or the median and interquartile
ranges where appropriate. Categorical variables are pre-
sented as percentages or proportion. For the univariate
analysis, we compared two groups using the Student’s t
test when normally distributed, and the Mann–Whitney
test when not. The Pearson χ2 test and the Kruskal-
Wallis test were applied for analysis of nominal and or-
dinal variables, respectively.
The univariate analysis was conducted to screen the risk
factors at a significant level of 0.20. Multivariate logistic
regression analysis was performed to assess the impact of
AKI and ACKI on the all-cause and cardiovascular in-
hospital mortality. The marked independent risk factors of
mortality were identified by stepwise method of Wald’s
forward selection. Adjusted odds ratio and the 95% confi-
dence interval for each notable risk factor in the modelwere derived. Similarly, the risk factors for development of
acute worsening of renal function were investigated using
variables obtained before the occurrence of acute renal in-
jury. Model calibration was assessed by using the Hosmer–
Lemeshow goodness-of-fit test. The variance inflation fac-
tor (VIF) was used for detecting the co-linearity and a VIF
of 10 and above indicates a co-linearity problem. All tests
were two-tailed and P< 0.05 was considered significant.
Data were analyzed using SPSS 13.0 for Windows
W.
Results
Comparison of clinical characteristics between AKI and ACKI
A total of 1,005 patients were included in the study.
Among them, 738 patients had index eGFR equal or above
60 ml/min/1.73 m2 and 267 patients had CKD with index
eGFR 30–59 ml/min/1.73 m2. The characteristics and
comparison between two groups are listed in Table 1.
Compared with patients with preserved renal function,
the patients with CKD were older and had more coexisted
diseases such as diabetes mellitus, hypertension, ischemic
heart disease and cerebrovascular disease. Patients with
CKD had lower concentration of serum albumin and
hemoglobin and higher levels of blood pressure compared
with patients without CKD.
According to the RIFLE criteria, acute worsening of
renal function occurred in 445 (44.3%) patients of the co-
hort. As shown in Table 2, the incidence of acute worsen-
ing of renal function was higher among patients with pre-
existed CKD than among those without. Additionally, the
proportion of patients with severe acute worsening of
renal function (injury and failure category) and those who
need renal replacement therapy (RRT) were more preva-
lent in CKD group. Notably, 19 patients in ACKI group
received RRT, only 9 patients were in Failure category.
Ten patients treated with RRT due to fluid overload
(n= 6), hyperkalemia (n= 2) or severe acidosis (n= 2).
Since diuretic resistance is the most extreme manifest-
ation of ADHF and associated with the adverse outcomes
[18], we compared the incidence of diuretic resistance
during hospitalization in patients with and without pre-
existed CKD. As shown in Table 2, diuretic resistance
seemed more prevalent in patients with ACKI than those
with AKI (23.8% vs. 17.7%), although the difference did
not reach statistical significance. However, more patients
with ACKI needed ultrafitration for diuretic resistance
compared to those with AKI.
Impact of AKI and ACKI on outcomes
In-hospital mortality and length of stay
In-hospital outcomes in patients classified by the index
eGFR were shown in Table 3. In patients with AKI, the
all-cause in hospital mortality was 16.7% and the cardio-
vascular mortality was 11.9%. While in those with ACKI,
the all-cause in hospital mortality was 24.5% and the
Table 1 Characteristics of patients classified by the index eGFR
Total cohort
(n = 1005)
Index eGFR (ml/min/1.73 m2)
≥60 (n = 738) 30~ 59 (n= 267) P
Demographics
Age, years 63 ± 16 60 ± 16 71 ± 12 <0.001
Male, no. (%) 625(62.2) 461(62.5) 164(61.4) 0.763
Current smoker, no. (%) 317(31.5) 240(32.5) 77(28.8) 0.267
Comorbid conditions
Diabetes, no. (%) 368(36.6) 243(32.9) 125(46.8) <0.001
Hypertension, no. (%) 485(48.3) 304(41.2) 181(67.8) <0.001
Ischemic heart disease, no. (%) 506(50.3) 354(48.0) 152(56.9) 0.012
Atrial fibrillation, no. (%) 288(28.7) 217(29.4) 71(26.6) 0.384
Cerebrovascular disease, no. (%) 112(11.1) 71(9.6) 41(15.4) 0.011
Comorbid sum a, no. (%) <0.001
0 118(11.7) 104(14.1) 14(5.2)
1 305(30.3) 250(33.9) 55(20.6)
2 347(34.5) 242(32.8) 105(39.4)
≥3 235(23.4) 142(19.2) 93(34.9)
Index eGFR, ml/min/1.73 m2 78 ± 25 89 ± 18 47 ± 9 <0.001
Characteristics on admission
LVEF< 45%, no. (%) 417(41.5) 305(41.3) 112(41.9) 0.860
NYHA class 4, no. (%)b 467(46.5) 315(42.7) 152(56.9) <0.001
Systolic blood pressure, mm Hg 130 ± 20 127 ± 19 136 ± 23 <0.001
Diastolic blood pressure, mm Hg 80± 22 79 ± 18 84 ± 30 0.002
Serum creatinine, μmol/L 110 ± 64 90 ± 31 164 ± 95 <0.001
Fasting plasma glucose, mmol/L 6.5 ± 2.3 6.4 ± 2.3 6.6 ± 2.6 0.385
Serum triglyeride, mmol/L 1.5 ± 1.4 1.4 ± 1.3 1.6 ± 1.6 0.353
Serum total cholesterol, mmol/L 4.6 ± 1.4 4.6 ± 1.4 4.6 ± 1.3 0.579
Serum LDL-C, mmol/L 2.3 ± 1.0 2.4 ± 1.0 2.3 ± 1.0 0.564
Serum albumin, g/L 36.2 ± 5.6 36.7 ± 5.2 34.6 ± 6.2 <0.001
Haemoglobin, g/L 128 ± 23 131 ± 22 118 ± 24 <0.001
Inotropic therapy, no. (%) 134(13.3) 104(14.1) 30(11.2) 0.239
a Number of comorbid conditions in a patient.
b NYHA class captured according to the manifestation during the first day of hospitalization.
Abbreviation: AHF, acute heart failure; eGFR, estimated glomerular filtration rate; LDL-C, low density lipoprotein cholesterol; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association.
Zhou et al. BMC Nephrology 2012, 13:51 Page 4 of 10
http://www.biomedcentral.com/1471-2369/13/51cardiovascular mortality was 23.2%. The incidence of all-
cause as well as cardiac death was significantly higher in
patients with ACKI than those with AKI (P< 0.05 in all).
Acute worsening of renal function during hospitalization
significantly increased all-cause and cardiac death in
both AKI and ACKI (Table 3). With respect to patients
with acute worsening of renal function, there was a step-
wise increase in the incidence of all-cause and cardiac
mortality from RIFLE category risk to category failure in
both AKI and ACKI (Table 3).
Development of acute worsening of renal function sig-
nificantly prolonged the length of stay in CCU as well as
in hospital. The severity of AKI defined by RIFLE categorycorrelated with length of stay in CCU and hospital. A
similar trend was observed among patients with ACKI.
Renal recovery
Full renal recovery was achieved in 177 (72.3%) of those in
AKI group at discharge, 67 (27.3%) partially recovered,
and 1 (0.4%) failed to recover. In contrast, in ACKI group,
full recovery was achieved in only 35 (30.7%) at discharge,
partial recovery was achieved in 73 (64.0%), and 6 (5.3%)
remained on dialysis at 90 days.
As shown in Figure 1, at any level of acute worsening
of renal function, ACKI group had significantly less pro-
portion of renal recovery as compared with AKI group.
Table 2 The characteristics of acute worsening of renal function in patients classified by the index eGFR
Total Index eGFR (ml/min/1.73 m2)
≥60 30~ 59 P
AWRF incidence, n/N (%) 445/1005 (44.3) 294/738 (39.8) 151/267 (56.6) <0.001
RIFLE category of AWRF, n/N (%) <0.001
Risk 282/445 (63.4) 204/294 (69.4) 78/151 (51.7)
Injury 127/445 (28.5) 63/294 (21.4) 64/151 (42.4)
Failure 36/445(18.1) 27/294 (9.2) 9/151 (6.0)
Maximum serum creatinine during hospitalization, μmol/L 182 ± 118 145 ± 73 254 ± 152 <0.001
Median time of maximum RIFLE class reached a, day 4 (1 ~ 8) 4(1 ~ 8) 4(2 ~ 8) 0.118
RRT required, n/N (%) 25/445 (5.6) 6/294 (2.0) 19/151 (12.6) <0.001
Diuretic resistance, n/N (%) 88/445(19.8) 52/294(17.7) 36/151(23.8) 0.123
Ultrafitration for diuretic resistance, n/N (%) 19/445(4.3) 6/294 (2.0) 13/151 (8.6) 0.002
a Values expressed as median (25th percentile -75th percentile).
Abbreviation: AWRF, acute worsening of renal function; eGFR, estimated glomerular filtration rate; RIFLE, risk, injury, failure, loss, end-stage renal disease; RRT,
renal replacement therapy.
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Re-hospitalization rate also represents an important out-
come. As shown in Table 4, one-year re-hospitalization for
subsequent ADHF and total reasons after the index
hospitalization was significantly higher in both AKI and
ACKI compared to those with ADHF alone. Notably, de-
velopment of ACKI during the index hospitalization sig-
nificantly increased subsequent one-year re-hospitalization
for both ADHF and total reasons as compared with those
with AKI.
The factors correlated with the outcomes of AKI and ACKI
To identify the factors correlated with in-hospital mortality,
we conducted univariate and multivariate logistic regres-


















23(5.2) 49(16.7) a 15(7.4) 16(25.4) 18(66.7)
Cardiovascular
mortality, no. (%)




3(2 ~ 4) 3(2 ~ 4) a 3(2 ~ 4) 3(2 ~ 4) 4(3 ~ 9)
Length of stay
in hospital, days
8(6 ~ 14) 14(9 ~ 18) a 12(8 ~ 17) 17(12~ 27) 20(15~ 3
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Abbreviation: ACKI, acute-on-chronic kidney injury; AKI, acute kidney injury; AWRF,
glomerular filtration rate.Table 5 showed adjusted odd ratios for all-cause mortality
in the total cohort and in the subgroups classified by index
eGFR. Pre-existed CKD and development of acute worsen-
ing of renal function during hospital were still the inde-
pendent risk factors for all-cause mortality in total cohort
after adjustment by age, gender, smoking, blood pressure,
LDL or HDL cholesterol, serum albumin, hemoglobin, co-
morbid diseases, and renal function (serum creatinine and
eGFR) on admission.
Likewise, severe acute worsening of renal function
(RIFLE category Injury or Failure) was one of the stron-
gest risk factors in ADHF patients with or without pre-
existed CKD when the analysis was separately conducted
in the subgroups. Severe heart failure (NYHA class 4)
and diuretic resistance were significant risk factors forg of renal function














<0.001 11(9.5) 37(24.5) a, b 11(14.1) 21(32.8) 5(55.6) 0.003
<0.001 8(6.9) 35(23.2) a, b 11(14.1) 19 (29.7) 5 (55.6) 0.005
0.001 4(2 ~ 4) 5(4 ~ 6) a,b 4(4 ~ 5) 5(4 ~ 6) 7(4 ~ 7) 0.027
3) <0.001 8(6 ~ 13) 15(11 ~ 22) a, b 14(8 ~ 18) 18(14 ~ 23) 20(9 ~ 32) 0.001
son among RIFLE category.





















Index eGFR       60 ml/min/1.73m2
Index eGFR 30~59 ml/min/1.73m2
Figure 1 Full renal recovery rate at discharge in patients with
AKI and ACKI stratified by RIFLE criteria. At any level of acute
worsening of renal function, ACKI group had less proportion of full
renal recovery as compared with AKI group.
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risk factors have been identified for cardiovascular mor-
tality in the cohort (Table 6).
Multivariate logistic regression analysis was also per-
formed to identify the risk factors for development of
acute worsening of renal function. As shown in Table 7,
the independent risk factors for acute worsening of renal
function in ADHF were diabetes, pre-existed CKD, sys-
tolic hear failure (LVEF< 45%) or severe heart failure
(NYHA class 4), severe systolic hypertension (systolic
blood pressure> 160 mmHg), and diuretic resistance.
Therapeutics approaches for management of HF might
also influence the outcomes. In our cohort, only 10 patients
received nesiritide treatment, probably due to exclusion of
those with cardiac shock before entry. A few patients had
been treated with cardiac resynchronization (n=20) or left-
ventricular assist devices (n=9). Therefore, we were not
able to analyze the effect of these approaches on the out-
comes because of the limited number of cases.
Discussion
Acute worsening of renal function in patients with
ADHF is common and increasingly recognized as anTable 4 One-year re-hospital rate in survival patients with acu
Index eGFR
≥60 (ml/min/1.73 m2)
No AWRF(n= 421) AKI group(n = 2
Total re-hospitalization, n (%) 80 (19.0) 64 (26.1)
For ADHF 16 (3.8) 22 (9.0)
For other reasons 64 (15.2) 42 (17.1)
Abbreviation: ACKI, acute-on-chronic kidney injury; ADHF, acute decompensated h
eGFR, estimated glomerular filtration rate.independent risk factor for morbidity and mortality [19-
23]. Renal impairment in ADHF develops as a conse-
quence of new onset kidney injury (AKI) or of acute de-
terioration of pre-existed CKD (ACKI). This study is the
first study, to the best of our knowledge, comparing the
prognostic implications of AKI with ACKI. The results
demonstrated that acute worsening of renal function in
ADHF was more prevalent in patients with pre-existed
CKD than those without. Patients with ACKI, as oppos-
ite to those with AKI, were at greater risk of adverse out-
comes during hospitalization for ADHF.
The reported incidence of acute worsening of renal
function in ADHF varies from 29% to 70% depending on
the study entry criteria and the definition used to
characterize renal dysfunction [3,24]. In our study, des-
pite exclusion of cardiogenic shock, contrast medium-
induced nephropathy, and severe chronic renal failure,
acute worsening of renal function was still very frequent
(44.3%) during hospitalization for ADHF. The incidence
was similar with the previous study which enrolled
patients with similar characteristics [25]. In contrast to
the most previous studies [2-4,23,26] in which serum
creatinine on admission or back-calculating creatinine
was used as the baseline renal function, we applied pre-
admission eGFR as the underlying renal function and
defined AKI and ACKI without bias [27]. An important
finding in our results was that ACKI was more frequent
than AKI (56.6% vs. 39.8%) in ADHF. Compared with
AKI, ACKI was associated with more severe renal injury
(defined as RIFLE category) and more proportion of
patients in this group required renal replacement ther-
apy during hospitalization. Consistent with the previous
report [24], worsening renal function occurred relatively
early in the course of the hospitalization with the me-
dian time of 4 days of maximum RIFLE class reached.
Diuretic resistance is common in ADHF, while its preva-
lence and prognostic implications are less well defined. It
is noteworthy that diuretic resistance in our cohort was
more prevalent among those with worsening renal func-
tion (23.8% in ACKI and 17.7% in AKI) than those with
ADHF alone (7.8% in those with pre-existed CKD and
4.7% in patients without CKD). In patients with worsening
renal function, prevalence of diuretic resistance seemed tote worsening of renal function
30~ 59 (ml/min/1.73 m2)
45) P No AWRF(n= 105) ACKI group(n = 114) P
0.031 19 (18.1) 38 (33.3) 0.010
0.005 3 (2.9) 16 (14.0) 0.003
0.509 16 (15.2) 22 (19.3) 0.428
eart failure; AKI, acute kidney injury; AWRF, acute worsening of renal function;
Table 5 Multivariate logistic regression analysis: risk factors for all-cause mortality
Total a Index eGFR (ml/min/1.73 m2)
≥60 b 30~ 59 c
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Cerebrovascular disease (yes vs. no) 1.86 (1.05 ~ 3.29) 0.034 - - - -
Index eGFR< 60 ml/min/1.73 m2 (yes vs. no) 1.66 (1.06 ~ 2.62) 0.028 NA NA NA NA
RIFLE category of AWRF (vs. no AWRF) 1.82 (1.14 ~ 2.90) 0.013 - <0.001 - 0.001
Risk - - 0.88 (0.43 ~ 1.79) 0.715 0.70 (0.26 ~ 1.91) 0.486
Injury - - 4.20 (1.96 ~ 9.01) <0.001 3.32 (1.36 ~ 8.08) 0.008
Failure - - 19.87 (6.35 ~ 44.79) <0.001 7.38(1.50 ~ 36.37) 0.014
LVEF< 45% on admission (yes vs. no) 2.16 (1.40 ~ 3.35) 0.001 1.88(1.07 ~ 3.31) 0.028 4.05 (1.91 ~ 8.60) <0.001
NYHA class 4 on admission (yes vs. no) 2.55 (1.55 ~ 4.20) <0.001 2.07(1.10 ~ 3.90) 0.024 5.50 (2.07 ~ 14.62) <0.001
Systolic blood pressure> 160 mmHg
on admission (yes vs. no)
2.30 (1.05 ~ 5.08) 0.039 - - - -
Fasting plasma glucose> 7.0 mmol/L
on admission (yes vs. no)
3.93 (2.54 ~ 6.07) <0.001 - - - -
Diuretic resistance (yes vs. no) 2.83 (1.72 ~ 4.64) <0.001 3.99 (2.01 ~ 7.90) <0.001 2.71 (1.17 ~ 6.28) 0.020
a Hosmer-Lemeshow goodness-of-fit test: chi-square value = 3.441, P = 0.841.
b Hosmer-Lemeshow goodness-of-fit test: chi-square value = 2.970, P = 0.888.
c Hosmer-Lemeshow goodness-of-fit test: chi-square value = 5.355, P = 0.719.
Abbreviation: AWRF, acute worsening of renal function; CI, confidence interval; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; OR, odd ratio;RIFLE, risk, injury, failure, loss, end-stage renal disease.
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mechanisms underlying diuretic resistance remain to be
clarified, it has been suggested that hypoalbuminemia,
commonly seen in CKD, may increase the volume distri-
bution of loop diuretics and impair their delivery to the
kidney [24]. Moreover, accumulation of organic acids in
CKD may act indirect competition with diuretics for se-
cretion at the proximal tubule [28]. Given the fact thatTable 6 Multivariate logistic regression analysis: risk factors f
Total a
OR (95% CI) P
Index eGFR< 60 ml/min/1.73 m2 (yes vs. no) 2.21 (1.37 ~ 3.58) 0.00




LVEF< 45% on admission (yes vs. no) 2.17 (1.35 ~ 3.51) 0.00
NYHA class 4 on admission (yes vs. no) 2.58 (1.48 ~ 4.50) 0.00
Systolic blood pressure> 160 mm Hg
on admission (yes vs. no)
2.74 (1.22 ~ 6.17) 0.01
Fasting plasma glucose> 7.0 mmol/L
on admission (yes vs. no)
3.98 (2.46 ~ 6.43) <0
Diuretic resistance (yes vs. no) 2.03 (1.19 ~ 3.49) 0.01
a Hosmer-Lemeshow goodness-of-fit test: chi-square value = 10.833, P = 0.146.
b Hosmer-Lemeshow goodness-of-fit test: chi-square value = 2.723, P = 0.843.
c Hosmer-Lemeshow goodness-of-fit test: chi-square value = 5.681, P = 0.577.
Abbreviation: AWRF, acute worsening of renal function; CI, confidence interval; eG
NYHA, New York Heart Association; OR, odd ratio;RIFLE, risk, injury, failure, loss, enddiuretic resistance, particularly with worsening renal func-
tion, results in marked persistent volume over-load in
ADHF [24], it may represents a subset of more advanced
HF and contribute to the poor outcomes. In this study, we
demonstrated that more patients with ACKI needed ultra-
fitration for diuretic resistance compared to those with
AKI. The presence of diuretic resistance was identified as
one of the strongest independent risk factors for all-causeor cardiovascular mortality
Index eGFR (ml/min/1.73 m2)
≥60 b 30~ 59 c
OR (95% CI) P OR (95% CI) P
1 NA NA NA NA
2 - <0.001 - <0.001
1.06 (0.48 ~ 2.33) 0.890 1.07 (0.37 ~ 3.08) 0.895
3.49 (1.48 ~ 8.26) 0.004 4.09 (1.56 ~ 10.70) 0.004
10.00 (3.74 ~ 26.76) <0.001 10.76 (2.12 ~ 54.48) 0.004
2 2.02(1.08 ~ 3.77) 0.028 3.37(1.55 ~ 7.30) 0.002
1 2.03 (1.02 ~ 4.06) 0.045 5.49 (1.92 ~ 15.71) 0.001
5 - - - -
.001 - - - -
0 2.21(1.03 ~ 4.74) 0.042 2.69(1.15 ~ 6.25) 0.022
FR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction;
-stage renal disease.
Table 7 Multivariate logistic regression analysis: risk factors for development of acute worsening of renal function
Total a Index eGFR (ml/min/1.73 m2)
≥60 b 30~ 59 c
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Diabetes (yes vs. no) 2.00(1.50 ~ 2.66) <0.001 1.74(1.24 ~ 2.43) 0.001 2.62(1.50 ~ 4.57) 0.001
Index eGFR< 60 ml/min/1.73 m2 (yes vs. no) 1.54 (1.13 ~ 2.11) 0.007 NA NA NA NA
LVEF< 45% on admission (yes vs. no) 1.73 (1.31 ~ 2.29) <0.001 1.59(1.15 ~ 2.20) 0.005 2.39(1.36 ~ 4.20) 0.002
NYHA class 4 on admission (yes vs. no) 3.10 (2.35 ~ 4.10) <0.001 3.53(2.55 ~ 4.89) <0.001 2.40(1.38 ~ 4.18) 0.002
Systolic blood pressure> 160 mmHg
on admission (yes vs. no)
3.80 (1.67 ~ 8.49) 0.001 4.07(1.23 ~ 13.42) 0.021 4.04(1.31 ~ 12.44) 0.015
Diuretic resistance (yes vs. no) 2.09 (1.55 ~ 2.81) <0.001 1.70(1.20 ~ 2.41) 0.003 3.63 (1.94 ~ 6.78) <0.001
a Hosmer-Lemeshow goodness-of-fit test: chi-square value = 4.722, P = 0.694.
b Hosmer-Lemeshow goodness-of-fit test: chi-square value = 2.437, P = 0.875.
c Hosmer-Lemeshow goodness-of-fit test: chi-square value = 7.809, P = 0.452.
Abbreviation: CI, confidence interval; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NA, not analysis; NYHA, New York Heart
Association; OR, odd ratio.
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those with pre-existed CKD (Table 4 & 5).
Renal dysfunction is one of the most important risk fac-
tors for poor outcomes in patients with ADHF [29,30].
However, the difference in prognostic implications between
AKI and ACKI has not been well established. Our results
demonstrated that patients with ACKI were at higher risk
of all-cause and cardiac mortality than those with AKI.
Among survivors in the cohort, those with ACKI had
longer hospital and CCU stay and higher re-hospitalization
as compared with AKI patients. Consistent with the previ-
ous study [31], the severity of acute kidney injury predicted
non-renal recovery, particularly in patients with AKI. The
patients with pre-existed CKD were older, and had more
co-morbid diseases such as diabetes, hypertension and is-
chemic heart disease. More proportion of those with back-
ground CKD had lower levels of serum albumin and
hemoglobin. To verify the impact of ACKI and AKI on
outcomes, logistic regression was used to adjust for the
possible confounding factors. In addition to known risk
factors, pre-existed CKD and acute worsening of renal
function during hospitalization were still found to be sig-
nificantly associated with all-cause and cardiac mortality.
Supporting with our results, in a community-based cohort
of patients with CKD, an episode of superimposed dialysis-
requiring ARF was associated with very high risk for non-
recovery of renal function [32]. In the multivariate logistic
regression analysis, we also found that pre-existed CKD
was an independent risk factor for development of acute
worsening of renal function during admission. When the
patients who died in hospital were excluded, full recovery
of renal function at discharge was 72.2% in those with AKI,
which was much lower than that in the population–base
studies (93%) [17] and also lower than that in patients with
post-trauma AKI (77.5%) [33]. It is noteworthy, creatinine
values were restored to previous levels in only 30.7% ofthose who had pre-existed CKD and survived their acute
illness, though we could not exclude the possibility that the
relatively low rate of renal recovery might be related to the
strict definition for full renal recovery used in the study.
RIFLE classification provides a well-stratification system
for acute renal injury and has been used more commonly
[34]. In our study, the RIFLE was able to predict all-cause
and cardiac mortality in both AKI and ACKI. The predict-
ive effect was still significant after adjustment by the con-
founding factors, suggesting that RIFLE classification
might be useful for stratification of patients with concomi-
tant cardiac and renal dysfunction. Consistent with early
report [35], the RIFLE criteria was suitable to evaluate the
AKI, as well as to predict its association with adverse out-
come in patients with ADHF.
Acute worsening of renal function in patients with
ADHF has been described as cardiorenal syndrome type
1 [36]. The previous reports studied the syndrome have
not differentiated AKI and ACKI. Our results indicated
that ACKI, as compared with AKI, was associated with
higher risk of adverse outcomes, suggesting that type 1
cardiorenal syndrome should be classified in two sub-
groups based on the underlying renal function. Since the
prevalence of CKD has been increasing, particularly in
those with cardiovascular disease, it is important to
identify CKD early. Estimated GFR should be included
in the assessment of risk stratification for individual
patients with cardiovascular disease, in addition to trad-
itional cardiovascular risk factors. Since ACKI increased
mortality and treatment cost, the need for adequate def-
inition and early screening has never been greater.
We classified ACKI based on RIFLE criteria. This classi-
fication may have missed a significant number of patients
because those with preexisted CKD would require a con-
siderable increase in creatinine to enter this classification
(e.g., a baseline creatinine of 200 μmol/L requires a rise to
Zhou et al. BMC Nephrology 2012, 13:51 Page 9 of 10
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criteria for ACKI therefore needs further study and
definition.
Conclusion
Our study compared the prognostic implications between
AKI and ACKI in a cohort of 1,005 Chinese patients with
ADHF. The results showed that ACKI was more frequent
than AKI in ADHF. As compared with AKI, ACKI was
associated with higher risk of in-hospital mortality, diur-
etic resistance, prolonged hospital stay, and failure in renal
recovery. RIFLE classification predicted all-cause and car-
diac mortality in both AKI and ACKI, making it useful to
stratify the patients with concomitant cardiac and renal
dysfunction.
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